Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Professor of Pathology and Biochemistry
Director, Laboratory for Clinical Biochemistry Research
University of Vermont College of Medicine
Burlington, Vermont

Topics of Professional Interest:

The molecular epidemiology of coagulation, fibrinolysis, and inflammation; emphasis on innate and adaptive immunity; all studied with respect to the etiology of atherosclerosis and coronary heart disease; cardiovascular risk prediction; murine models of atherosclerosis; and, chronic diseases of old age.

 

Current Professional Summary:

Dr Tracy’s approach to research reflects his training in biochemistry and clinical chemistry, and his long interest in population-based science. Areas of research include the interrelationships of coagulation, fibrinolysis and inflammation, especially the innate and adaptive immune systems, in the etiology of atherosclerosis and coronary heart disease, insulin resistance and diabetes, HIV-related morbidity and mortality, and other complex diseases, as well as more broadly in the process of aging. The main tools of the laboratory are those of molecular and genetic epidemiology, in the context of multi-center studies and clinical research. More basic biochemical approaches are used in the development of new assays for epidemiological application. He has a long standing interest in disease risk modeling and risk assessment as well as in developing new biomarkers for clinical and epidemiological research. He also collaborates on studies of murine models of atherosclerosis with Dr Sally Huber of the Pathology Department.

Education:
  • 1967 - 1971: Undergraduate Student, Biology, LeMoyne College, Syracuse, NY (BS)
  • 1973 - 1978: Graduate Student, Biochemistry, Syracuse University, Syracuse, NY (PhD)
  • 1978 - 1980: Post-Doctoral Training Fellow, Clinical Chemistry, Mayo Clinic, Rochester, MN
Selected Publications:
  1. Hunt PW, Martin JN, Sinclair E, et al.Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15;203(10):1474-1483.
  2. Duprez DA, Neuhaus J, Tracy R, et al. N-terminal-prob-type natriuretic peptide predicts cardiovascular disease events in hiv-infected patients. AIDS. 2011;25(5):651-657.
  3. Fitzpatrick AL, Kronmal RA, Kimura M, et al. Leukocyte telomere length and mortality in the Cardiovascular Health Study. J Gerontol Biol Sci Med Sci. 2011;66(4): 421-429.
  4. Carty CL, Heagerty P, Heckbert SR, et al. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study.  Ann of Hum Genet. 2010;74(1):1–10.
  5. Schnabel RB, Baumert J, Barbalic M, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood. 2010;115(26):5289-5299. 

Presentations

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management